vs
Side-by-side financial comparison of Insulet Corporation (PODD) and UMB FINANCIAL CORP (UMBF). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $739.2M, roughly 1.1× UMB FINANCIAL CORP). UMB FINANCIAL CORP runs the higher net margin — 35.4% vs 13.0%, a 22.4% gap on every dollar of revenue. On growth, UMB FINANCIAL CORP posted the faster year-over-year revenue change (321.6% vs 31.2%). Over the past eight quarters, UMB FINANCIAL CORP's revenue compounded faster (73.7% CAGR vs 33.2%).
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
UMB Financial Corporation is an American financial services company headquartered in Kansas City, Missouri. It offers comprehensive financial services, including deposit solutions like checking and savings accounts, credit services including home mortgages, auto loans, business loans and credit cards, as well as investing and wealth management. UMB serves individuals, companies and institutions across the U.S. and in Ireland.
PODD vs UMBF — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $783.7M | $739.2M |
| Net Profit | $101.6M | $261.4M |
| Gross Margin | 72.6% | — |
| Operating Margin | 18.7% | — |
| Net Margin | 13.0% | 35.4% |
| Revenue YoY | 31.2% | 321.6% |
| Net Profit YoY | 0.9% | 221.4% |
| EPS (diluted) | $1.42 | $3.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $739.2M | ||
| Q4 25 | $783.7M | $522.5M | ||
| Q3 25 | $706.3M | $475.0M | ||
| Q2 25 | $649.1M | $467.0M | ||
| Q1 25 | $569.0M | $397.6M | ||
| Q4 24 | $597.5M | $269.0M | ||
| Q3 24 | $543.9M | $247.4M | ||
| Q2 24 | $488.5M | $245.1M |
| Q1 26 | — | $261.4M | ||
| Q4 25 | $101.6M | $215.4M | ||
| Q3 25 | $87.6M | $188.3M | ||
| Q2 25 | $22.5M | $217.4M | ||
| Q1 25 | $35.4M | $81.3M | ||
| Q4 24 | $100.7M | $120.0M | ||
| Q3 24 | $77.5M | $109.6M | ||
| Q2 24 | $188.6M | $101.3M |
| Q1 26 | — | — | ||
| Q4 25 | 72.6% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 69.7% | — | ||
| Q1 25 | 71.9% | — | ||
| Q4 24 | 72.1% | — | ||
| Q3 24 | 69.3% | — | ||
| Q2 24 | 67.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 18.7% | 51.7% | ||
| Q3 25 | 16.7% | 49.8% | ||
| Q2 25 | 18.7% | 58.9% | ||
| Q1 25 | 15.6% | 23.4% | ||
| Q4 24 | 18.3% | 53.8% | ||
| Q3 24 | 16.2% | 54.8% | ||
| Q2 24 | 11.2% | 51.8% |
| Q1 26 | — | 35.4% | ||
| Q4 25 | 13.0% | 41.2% | ||
| Q3 25 | 12.4% | 39.6% | ||
| Q2 25 | 3.5% | 46.5% | ||
| Q1 25 | 6.2% | 20.5% | ||
| Q4 24 | 16.9% | 44.6% | ||
| Q3 24 | 14.2% | 44.3% | ||
| Q2 24 | 38.6% | 41.3% |
| Q1 26 | — | $3.35 | ||
| Q4 25 | $1.42 | $2.90 | ||
| Q3 25 | $1.24 | $2.36 | ||
| Q2 25 | $0.32 | $2.82 | ||
| Q1 25 | $0.50 | $1.21 | ||
| Q4 24 | $1.38 | $2.44 | ||
| Q3 24 | $1.08 | $2.23 | ||
| Q2 24 | $2.59 | $2.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $930.8M | $477.2M |
| Stockholders' EquityBook value | $1.5B | $7.8B |
| Total Assets | $3.2B | $72.7B |
| Debt / EquityLower = less leverage | 0.61× | 0.06× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $7.8B | ||
| Q3 25 | — | $8.8B | ||
| Q2 25 | — | $11.0B | ||
| Q1 25 | — | $10.6B | ||
| Q4 24 | — | $8.4B | ||
| Q3 24 | — | $7.3B | ||
| Q2 24 | — | $5.0B |
| Q1 26 | — | $477.2M | ||
| Q4 25 | $930.8M | $474.2M | ||
| Q3 25 | $934.9M | $471.3M | ||
| Q2 25 | $939.0M | $657.3M | ||
| Q1 25 | $1.6B | $654.4M | ||
| Q4 24 | $1.3B | $385.3M | ||
| Q3 24 | $1.4B | $384.8M | ||
| Q2 24 | $1.4B | $384.2M |
| Q1 26 | — | $7.8B | ||
| Q4 25 | $1.5B | $7.7B | ||
| Q3 25 | $1.4B | $7.4B | ||
| Q2 25 | $1.5B | $7.3B | ||
| Q1 25 | $1.3B | $6.7B | ||
| Q4 24 | $1.2B | $3.5B | ||
| Q3 24 | $1.1B | $3.5B | ||
| Q2 24 | $998.4M | $3.2B |
| Q1 26 | — | $72.7B | ||
| Q4 25 | $3.2B | $73.1B | ||
| Q3 25 | $3.0B | $71.9B | ||
| Q2 25 | $3.5B | $71.8B | ||
| Q1 25 | $3.5B | $69.3B | ||
| Q4 24 | $3.1B | $50.4B | ||
| Q3 24 | $3.0B | $47.5B | ||
| Q2 24 | $2.9B | $44.5B |
| Q1 26 | — | 0.06× | ||
| Q4 25 | 0.61× | 0.06× | ||
| Q3 25 | 0.68× | 0.06× | ||
| Q2 25 | 0.64× | 0.09× | ||
| Q1 25 | 1.21× | 0.10× | ||
| Q4 24 | 1.07× | 0.11× | ||
| Q3 24 | 1.21× | 0.11× | ||
| Q2 24 | 1.36× | 0.12× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.3M | — |
| Free Cash FlowOCF − Capex | $48.2M | — |
| FCF MarginFCF / Revenue | 6.2% | — |
| Capex IntensityCapex / Revenue | 17.2% | — |
| Cash ConversionOCF / Net Profit | 1.80× | — |
| TTM Free Cash FlowTrailing 4 quarters | $377.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $183.3M | $106.1M | ||
| Q3 25 | $125.7M | $272.2M | ||
| Q2 25 | $196.5M | $285.4M | ||
| Q1 25 | $63.8M | $363.0M | ||
| Q4 24 | $147.7M | $-66.9M | ||
| Q3 24 | $98.5M | $123.6M | ||
| Q2 24 | $96.5M | $112.4M |
| Q1 26 | — | — | ||
| Q4 25 | $48.2M | $95.3M | ||
| Q3 25 | $100.1M | $257.8M | ||
| Q2 25 | $177.9M | $270.8M | ||
| Q1 25 | $51.5M | $354.2M | ||
| Q4 24 | $94.1M | $-77.1M | ||
| Q3 24 | $71.8M | $117.7M | ||
| Q2 24 | $74.0M | $106.7M |
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | 18.2% | ||
| Q3 25 | 14.2% | 54.3% | ||
| Q2 25 | 27.4% | 58.0% | ||
| Q1 25 | 9.1% | 89.1% | ||
| Q4 24 | 15.7% | -28.6% | ||
| Q3 24 | 13.2% | 47.6% | ||
| Q2 24 | 15.1% | 43.5% |
| Q1 26 | — | — | ||
| Q4 25 | 17.2% | 2.1% | ||
| Q3 25 | 3.6% | 3.0% | ||
| Q2 25 | 2.9% | 3.1% | ||
| Q1 25 | 2.2% | 2.2% | ||
| Q4 24 | 9.0% | 3.8% | ||
| Q3 24 | 4.9% | 2.4% | ||
| Q2 24 | 4.6% | 2.3% |
| Q1 26 | — | — | ||
| Q4 25 | 1.80× | 0.49× | ||
| Q3 25 | 1.43× | 1.45× | ||
| Q2 25 | 8.73× | 1.31× | ||
| Q1 25 | 1.80× | 4.46× | ||
| Q4 24 | 1.47× | -0.56× | ||
| Q3 24 | 1.27× | 1.13× | ||
| Q2 24 | 0.51× | 1.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
UMBF
Segment breakdown not available.
